NASDAQ:GRCL Gracell Biotechnologies (GRCL) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$10.25▼$10.2550-Day Range$10.14▼$10.3552-Week Range$1.40▼$10.44VolumeN/AAverage Volume1.32 million shsMarket Capitalization$744.95 millionP/E RatioN/ADividend YieldN/APrice Target$11.88 Stock AnalysisStock AnalysisAnalyst ForecastsEarningsHeadlinesOwnershipShort InterestTrendsStock AnalysisAnalyst ForecastsEarningsHeadlinesOwnershipShort InterestTrends Get Gracell Biotechnologies alerts: Email Address Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Gracell Biotechnologies Stock (NASDAQ:GRCL)Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in phase 1 clinical trial for the treatment of relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL) in adult; and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 2 clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as hematologic cell malignancies and solid tumors. Gracell Biotechnologies Inc. was incorporated in 2017 and is headquartered in Suzhou, China. As of February 22, 2024, Gracell Biotechnologies Inc. operates as a subsidiary of AstraZeneca Treasury Limited.Read More Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. GRCL Stock News HeadlinesMarch 3, 2024 | finance.yahoo.comGRCL Mar 2024 10.000 call(CONTRFebruary 22, 2024 | finance.yahoo.comGracell Biotechnologies Acquisition CompletedJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.February 22, 2024 | globenewswire.comGracell Biotechnologies Acquisition CompletedFebruary 21, 2024 | seekingalpha.comAstraZeneca Deal For Gracell Biotechnologies Closing Tomorrow (Includes CVR)February 21, 2024 | investing.comGracell Biotechnologies Inc. (GRCL)February 20, 2024 | finanznachrichten.deGracell Biotechnologies Inc.: Gracell Biotechnologies Announces Shareholders' Approval of Merger AgreementFebruary 20, 2024 | finance.yahoo.comGracell Biotechnologies Announces Shareholders’ Approval of Merger AgreementJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.February 20, 2024 | globenewswire.comGracell Biotechnologies Announces Shareholders' Approval of Merger AgreementFebruary 17, 2024 | finance.yahoo.comGRCL Mar 2024 2.500 callFebruary 17, 2024 | seekingalpha.comGRCL Gracell Biotechnologies Inc.January 29, 2024 | finance.yahoo.comGracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple MyelomaJanuary 3, 2024 | finance.yahoo.comGracell Biotechnologies Inc. Sponsored ADR (GRCL) is a Great Momentum Stock: Should You Buy?December 31, 2023 | businesswire.comGRACELL BIOTECHNOLOGIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of ...December 27, 2023 | markets.businessinsider.comMaintaining Hold on Gracell Biotechnologies Amidst AstraZeneca Acquisition ProspectsDecember 26, 2023 | msn.comWhy China-Based Gracell Biotechnologies (GRCL) Stock Is Soaring TodayDecember 26, 2023 | finance.yahoo.comGracell Biotechnologies to be acquired by AstraZeneca, furthering cell therapy ambition across oncology and autoimmune diseasesSee More Headlines Receive GRCL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gracell Biotechnologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/14/2021Today7/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:GRCL CUSIPN/A CIK1826492 Webwww.gracellbio.com Phone86-512-6262-6701FaxN/AEmployees314Year FoundedN/APrice Target and Rating Average Stock Price Target$11.88 High Stock Price Target$20.00 Low Stock Price Target$10.00 Potential Upside/Downside+15.9%Consensus RatingHold Rating Score (0-4)2.38 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-88,080,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-37.40% Return on Assets-31.24% Debt Debt-to-Equity Ratio0.02 Current Ratio7.73 Quick Ratio7.73 Sales & Book Value Annual Sales$60,000.00 Price / Sales12,415.83 Cash FlowN/A Price / Cash FlowN/A Book Value$2.95 per share Price / Book3.47Miscellaneous Outstanding Shares72,678,000Free Float52,328,000Market Cap$744.95 million OptionableOptionable Beta-0.33 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report Key ExecutivesDr. Wei Cao BM (Age 65)Ph.D., Founder, Chairman & CEO Dr. Yili Xie M.B.A. (Age 53)Ph.D., Chief Financial Officer Dr. Samuel Suhua Zhang M.B.A. (Age 56)Ph.D., Chief Business Officer Dr. Wendy Li M.D. (Age 65)Chief Medical Officer Ms. Erin LiExecutive OfficerKey CompetitorsAllogene TherapeuticsNASDAQ:ALLOPoseida TherapeuticsNASDAQ:PSTXbluebird bioNASDAQ:BLUELianBioNASDAQ:LIANCelyad OncologyNASDAQ:CYADView All Competitors GRCL Stock Analysis - Frequently Asked Questions How were Gracell Biotechnologies' earnings last quarter? Gracell Biotechnologies Inc. (NASDAQ:GRCL) released its earnings results on Sunday, November, 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by $0.18. The business earned $0.06 million during the quarter. When did Gracell Biotechnologies IPO? Gracell Biotechnologies (GRCL) raised $150 million in an initial public offering on Friday, January 8th 2021. The company issued 8,800,000 shares at $16.00-$18.00 per share. Citigroup, Jefferies, Piper Sandler and Wells Fargo Securities served as the underwriters for the IPO. This page (NASDAQ:GRCL) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gracell Biotechnologies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gracell Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
